Hyderabad, March 28, 2019: Hyderabad, India and Princeton, NJ, USA. March 27, 2019— Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA).
The Cialis brand and generic had U.S. sales of approximately $1.7 billion MAT for the most recent twelve months ending in January 2019 according to IMS Health*.
Dr. Reddy’s Tadalafil Tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.
Cialis is a trademark of Eli Lilly and Company
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
Seniority encourages ‘Ageing with Independence’ to observe World Alzheimer’s Day
Buying a Water Filter Online!
Zendesk’s Double-Digit Growth in APAC Cements its Commitment to Developing Tech Talent Across the Region
Hungama’s latest Marathi original show, ‘Shree Kaamdev Prasanna’ crosses 43 lakh episodic views in 30 days!
Mother Dairy – Pioneers of Automated Bulk Milk Vending – Announces Pan-India Plastic Waste Collection & Recycling Drive
2014 The Global Indian New Network (TGINN)